About this trial
This study aims to evaluate the clinical effectiveness of the oXiris® hemofilter in patients with septic shock and acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT). While some studies suggest that oXiris® may improve hemodynamic stability by removing endotoxins and cytokines, its impact on survival remains inconsistent.To provide more reliable causal evidence, this multicenter retrospective cohort study utilizes a Target Trial Emulation (TTE) approach. The study will compare patients treated with the oXiris® filter to those treated with standard CRRT filters, focusing on in-hospital mortality and other clinical outcomes such as fluid balance and vasopressor requirements.
Eligibility criteria
Qualifiers
Adults aged 19 years or older.
Admitted to the ICU with septic shock (Sepsis-3 criteria) between March 2021 and August 2025.
Required Continuous Renal Replacement Therapy (CRRT) due to acute kidney injury (AKI).
Disqualifiers
Death or withdrawal of life-sustaining therapy within 48 hours of ICU admission.
Patients with End-Stage Renal Disease (ESRD).
Patients with missing critical covariates.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Seoul National University Bundang Hospital
Lead sponsor
Vantive Health LLC
Collaborator